Overview

A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This trial is a multi-center, open-label, phase I, dose escalation study of PEP02 (liposomal encapsulated irinotecan) in combination with 5-FU and LV in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
PharmaEngine
Treatments:
Fluorouracil
Irinotecan
Leucovorin